此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

2020年12月8日 更新者:University of Washington

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy

This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.

研究概览

详细说明

OUTLINE:

Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.

研究类型

观察性的

注册 (实际的)

2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutch/University of Washington

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

男性

取样方法

非概率样本

研究人群

Participants with prostate adenocarcinoma

描述

Inclusion Criteria:

  • Signed informed consent
  • Histologically confirmed adenocarcinoma of the prostate
  • Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
  • No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
  • Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:

    • Prior myocardial infarction >= 30 days before enrollment
    • Prior revascularization procedure >= 30 days before consent, including:

      • Coronary artery stent placement or balloon angioplasty
      • Coronary artery bypass graft surgery
      • Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
      • Carotid endarterectomy surgery
      • Vascular bypass surgery of the iliac, femoral, or popliteal artery
    • Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
    • Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
    • Ankle-brachial pressure index < 0.9 at any time point before enrollment
  • Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months

Exclusion Criteria:

  • No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
  • Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
  • Plans to start or continue treatment with an investigational product after enrollment
  • Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
  • Prior or planned surgical castration
  • Poorly controlled hypertension at time of study entry, as judged by the investigator
  • Myocardial infarction or stroke < 30 days prior to enrollment
  • Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
  • Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
  • Mental incapacity or language barrier precluding adequate understanding or cooperation
  • Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
  • Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
  • Estimated glomerular filtration rate (eGFR) < 45
  • History of allergy to gadolinium contrast agent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
辅助研究
Undergo clinical evaluations

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
大体时间:12 Months
Change From Baseline visual characterization scan results at 12 months
12 Months
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
大体时间:12 Months
Change from baseline standardized uptake values in select regions of interest at 12 months
12 Months

次要结果测量

结果测量
措施说明
大体时间
Cognitive test results: Story recall
大体时间:12 months
Change in baseline Story Recall results at 12 months
12 months
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
大体时间:12 Months
Change in baseline MOCA score results at 12 months
12 Months
Cognitive Test Results: Change in Clinical Dementia Rating Scale
大体时间:12 Months
Change in baseline Clinical Dementia Rating Scale score at 12 months
12 Months
Cognitive Test Results: Digit span
大体时间:12 Months
Change in baseline Digit span results at 12 months
12 Months
Cognitive Test Results: Letter number sequencing
大体时间:12 Months
Change in baseline Letter number sequencing results at 12 months
12 Months
Cognitive Test Results: Stroop Test Results
大体时间:12 Months
Change in baseline Stroop Test Results at 12 months
12 Months
Cognitive Test Results: Symbol Digit Modalities Test
大体时间:12 Months
Change in baseline Symbol Digit Modalities Test score at 12 months
12 Months
Cognitive Test Results: Visuo-Spatial Learning Test
大体时间:12 Months
Change in baseline Visuo-Spatial Learning Test results at 12 months
12 Months
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
大体时间:12 Months
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
12 Months
Inflammatory and immune markers: Change in CRP
大体时间:12 Months
Change in baseline CRP values at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP3
大体时间:12 Months
Change in baseline IGFBP3 at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP1
大体时间:12 Months
Change in baseline IGFBP1 at 12 months
12 Months
Inflammatory and immune markers: Change in IGF-1
大体时间:12 Months
Change in baseline IGF-1 at 12 months
12 Months
Inflammatory and immune markers: Change in IL-6
大体时间:12 Months
Change in baseline IL-6 at 12 months
12 Months
Metabolic Markers: Change in HgbA1C
大体时间:12 Months
Change in baseline HgbA1C at 12 months
12 Months
Metabolic Markers: Change in Estradiol
大体时间:12 Months
Change in baseline Estradiol at 12 months
12 Months
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
大体时间:12 Months
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
12 Months
Metabolic Markers: Change in Leptin
大体时间:12 Months
Change in baseline Leptin at 12 months
12 Months
Metabolic Markers: Change in Adiponectin
大体时间:12 Months
Change in baseline Adiponectin at 12 months
12 Months
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
大体时间:12 Months
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
12 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Evan Yu、Fred Hutch/University of Washington Cancer Consortium

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年10月8日

初级完成 (实际的)

2020年3月12日

研究完成 (实际的)

2020年3月12日

研究注册日期

首次提交

2018年9月12日

首先提交符合 QC 标准的

2018年10月22日

首次发布 (实际的)

2018年10月24日

研究记录更新

最后更新发布 (实际的)

2020年12月10日

上次提交的符合 QC 标准的更新

2020年12月8日

最后验证

2020年12月1日

更多信息

与本研究相关的术语

其他研究编号

  • RG1001903
  • 9939 (FHCRC)
  • NCI-2018-01618 (注册表标识符:CTRP)
  • 5P30CA015704 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅